Evidence map›Paper›PMID 40389477›Full record

ArticleNature communications2025

Dual Ribosome Profiling reveals metabolic limitations of cancer and stromal cells in the tumor microenvironment.

Daniela Aviles-Huerta, Rossella Del Pizzo, Alexander Kowar, Ali Hyder Baig, Giuliana Palazzo, Ekaterina Stepanova, Cinthia Claudia Amaya Ramirez, Sara D'Agostino, Edoardo Ratto, Catarina Pechincha and 11 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Daniela Aviles-Huerta *Translational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Rossella Del Pizzo *Translational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Alexander KowarTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-7868-3935
Ali Hyder BaigTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Giuliana PalazzoTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Ekaterina StepanovaTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Cinthia Claudia Amaya RamirezTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Sara D'AgostinoTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Edoardo RattoFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4104-7556
Catarina PechinchaFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-4650-4250
Nora SiefertFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.ORCID http://orcid.org/0000-0002-1101-2264
Helena EngelFaculty of Biosciences, University of Heidelberg, Heidelberg, Germany.
Shangce DuImmune Regulation in Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Silvia Cadenas-De MiguelDepartment of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.
Beiping MiaoImmune Regulation in Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Victor M Cruz-VilchezTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.ORCID http://orcid.org/0009-0008-5269-4987
Karin Müller-DeckerCore Facility Tumor Models, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Ilaria EliaDepartment of Cellular and Molecular Medicine, KU Leuven, 3000, Leuven, Belgium.ORCID http://orcid.org/0000-0003-0922-9429
Chong SunImmune Regulation in Cancer, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.
Wilhelm PalmDivision of Cell Signaling and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany.ORCID http://orcid.org/0000-0003-0612-770X
Fabricio Loayza-PuchTranslational Control and Metabolism, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 280, Heidelberg, Germany. f.loayza-puch@dkfz-heidelberg.de.ORCID http://orcid.org/0000-0002-2999-8594

Funding

Deutsche Forschungsgemeinschaft (German Research Foundation) 504774163Deutsche Forschungsgemeinschaft (German Research Foundation) 545215964EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) 759579
6 · The paper itself

Abstract

The tumor microenvironment (TME) influences cancer cell metabolism and survival. However, how immune and stromal cells respond to metabolic stress in vivo, and how nutrient limitations affect therapy, remains poorly understood. Here, we introduce Dual Ribosome Profiling (DualRP) to simultaneously monitor translation and ribosome stalling in multiple tumor cell populations. DualRP reveals that cancer-fibroblast interactions trigger an inflammatory program that reduces amino acid shortages during glucose starvation. In immunocompetent mice, we show that serine and glycine are essential for optimal T cell function and that their deficiency impairs T cell fitness. Importantly, immune checkpoint blockade therapy imposes amino acid restrictions specifically in T cells, demonstrating that therapies create distinct metabolic demands across TME cell types. By mapping codon-resolved ribosome stalling in a cell‑type‑specific manner, DualRP uncovers metabolic crosstalk that shapes translational programs. DualRP thus offers a powerful, innovative approach for dissecting tumor cell metabolic interplay and guiding combined metabolic-immunotherapeutic strategies.

Indexed as

NeoplasmsRibosomesStromal CellsTumor MicroenvironmentAmino AcidsAnimalsCell Line, TumorFemaleFibroblastsGlycineHumansMiceMice, Inbred C57BLProtein BiosynthesisRibosome ProfilingSerineAmino AcidsGlycineSerine

Identifiers

PMID40389477
PMCPMC12089342

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.